This work, and that of colleagues Brian Druker and Novartis, led to the development of the kinase inhibitor imatinib (Gleevec) as primary therapy for chronic myelogenous leukemia (CML), and the discovery that imatinib resistance is caused by BCR -
ABL kinase domain mutations.
Kinase domain mutants of Bcr - Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to im
Kinase domain mutants of Bcr -
Abl exhibit altered transformation potency,
kinase activity, and substrate utilization, irrespective of sensitivity to im
kinase activity, and substrate utilization, irrespective of sensitivity to imatinib